

A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

NCT07293897

Status RECRUITING
Sponsor Takeda
Enrollment 50 participants

Key Eligibility Criteria

Inclusion (2)

- Has a diagnosis of ALGS or PFIC within the enrollment period.
- There is a prescription for Livmarli during the enrollment period (Index date: the date of the first prescription within the enrollment period).

Exclusion (1)

- None

Locations (1 total)

Takeda selected site, Tokyo, Tokyo, Japan